Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%
Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...
precisionmedicineonline3h
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
precisionmedicineonline7h
Ibrance Plus Frontline Standard Therapy Delays Progression by 15 Months in HER2, HR-Positive Breast Cancer
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
Pfizer (PFE) Is Too Cheap To Ignore
Pfizer just raised its dividend by 2.4% to $0.43, giving investors something to cheer about despite the stock’s lackluster ...